Hoth Therapeutics, a clinical-stage biopharmaceutical company, has filed two U.S. provisional patent applications that significantly expand its intellectual property portfolio and establish a new oncology-focused dermatology platform targeting treatment-induced skin toxicity from modern cancer therapies.

The filings secure priority intellectual property rights around the use of HT-001 to treat dermatologic toxicities across multiple oncology treatment modalities, including radiation therapy and next-generation targeted agents.

HT-001 is a receptor antagonist with a well-established pharmacologic profile. Hoth’s patent filings seek to protect the use of HT-001 to target neurogenic and inflammatory pathways implicated in therapy-induced skin injury. The company believes this approach may represent a novel and potentially first-in-class strategy within the rapidly expanding oncology supportive-care and oncodermatology markets.

“These filings represent a meaningful expansion of our intellectual property estate into an increasingly important area of oncology care,” said Robb Knie of Hoth Therapeutics. “As cancer therapies advance, the ability to manage treatment-related toxicities is becoming essential. We believe this emerging platform highlights our strategy of identifying differentiated, mechanism-driven opportunities that can address significant unmet needs while creating long-term shareholder value.”

The company believes these provisional patents support the development of a scalable oncology-adjacent platform with potential applications across radiation oncology, targeted cancer therapies, dermatology, and inflammatory skin disorders, while leveraging an established compound in novel therapeutic contexts, formulations, and routes of administration. The filings also provide flexibility to pursue additional preclinical development, formulation optimization, and future U.S. and international patent protection.

More Hoth Therapeutics News

In August, Hoth Therapeutics entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic.